← board
RVPH
Reviva Pharmaceuticalsdistress 4/10 · elevated risk$0.50+19%today-97% from 52w high
Psychiatry / CNS 1
Lead: schizophrenia · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$22M
Runway
1.1 yrs
Shares 1y
-81%
Price & events
-92.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+19.0%
1D
-9.3%
1W
-28.1%
1M
-43.8%
3M
-92.3%
6M
-94.1%
1Y
-97.6%
2Y
-99.3%
5Y
-99.7%
All
Overview
- Market Cap
- $6.56M
- Volume
- 7.95K
- 52 Week Range
- $0.33 – $16.80
- Total Shares
- 13.11M
- Float Shares
- 11.38M
- Short %
- 14.95%
- % Held by Insiders
- 7.73%
- % Held by Institutions
- 12.78%
- RVOL
- 0.14x
- Beta
- 0.47
Pipeline stages · 1 programs
Brilaroxazine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-02 | Phase 3 | Brilaroxazine | Schizophrenia | 690 | recruiting |
Catalyst news & presentations · 9
- fourth quarter of 2028Guided 70%PDUFAPDUFAbrilaroxazine · Potential FDA approval of brilaroxazineSEC 8-K
- Q4 2027Guided 70%readoutPhase 3brilaroxazine · Topline data from RECOVER-2 Phase 3 trial in schizophreniaSEC 8-K
- fourth quarter of 2027Guided 70%regulatory submissionFiled (NDA/BLA)brilaroxazine · NDA filing for brilaroxazineSEC 8-K
- third quarter of 2027Guided 70%readoutPhase 3brilaroxazine · Negative Symptoms/Bipolar Trial data availableSEC 8-K
- second quarter of 2027Guided 70%readoutPhase 3brilaroxazine · RECOVER-2 data availableSEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- second quarter of 2026trial initiationsecondaryPhase 3brilaroxazine · Initiate Phase 3 trial for negative symptoms or bipolar disorderSEC 8-K
- 2026-05-14withdrawalNasdaq delisting effective May 14, 2026; stock moves to OTCQB.SEC 8-K
- 2025-12-23fda agreementbrilaroxazine · FDA recommended additional Phase 3 trial before NDA submission for schizophreniaSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $18 (+3400% upside) · 2 analysts
- 2026-04-08Maxim GroupBuy → Hold
- 2026-03-31Roth CapitalBuy
- 2026-03-30Alliance Global PartnersBuy
- 2026-03-05D. Boral CapitalBuy → Hold
- 2026-01-05Chardan CapitalBuy
- 2025-12-23D. Boral CapitalBuy
Competitors — schizophrenia
- NBIXNEUROCRINE BIOSCIENCES INC$17.2B · D0
- ALKSAlkermes plc.$8.7B · D0
- MPLTMapLight Therapeutics, Inc.$1.5B · D2
- LBRXLB PHARMACEUTICALS INC$1.0B · D2
- ANROAlto Neuroscience, Inc.$937M · D3
- NMRANeumora Therapeutics, Inc.$281M · D5
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- AVXLANAVEX LIFE SCIENCES CORP.$236M · D1
- NERVMinerva Neurosciences, Inc.$207M · D6
- BTAIBioXcel Therapeutics, Inc.$27M · D10
Recent news
- 2026-07-18Operating margin % of Reviva Pharmaceuticals Holdings, Inc. – OTC:RVPH - TradingView
- 2026-07-10Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) — Files Form 25 to remove Common Stock from Nasdaq listing - Stock Titan
- 2026-07-08Reviva Pharmaceuticals Holdings (RVPH) Plunges 10% as Key Support Nears - IV Expansion Alert - DonanımHaber
- 2026-07-08Reviva Pharmaceuticals (RVPH) Hovers Near Support Amid Minimal Price Movement - Donchian Channel - dars.gov.et
- 2026-07-08Reviva Pharmaceuticals (RVPH) Hovers Near Support Amid Minimal Price Movement - Momentum Breakout Ideas - dars.gov.et
- 2026-07-08Reviva Pharmaceuticals (RVPH) Lytham Partners Spring 2025 Investor Conference summary - Quartr
- 2026-07-08Reviva Pharmaceuticals Holdings (RVPH) Plunges 10% as Key Support Nears - Quality Factor - dars.gov.et
- 2026-07-07Diluted earnings per share (diluted EPS) of Reviva Pharmaceuticals Holdings, Inc. – OTC:RVPH - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.